Phase 1 study of KT-333, a targeted protein degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia, and solid tumors

被引：0
|
作者：
Starodub, Alexander
Gollerkeri, Ashwin
De Savi, Chris
Dey, Joyoti
Agarwal, Sagar
Donohue, Sean
Perea, Rachelle
Klaus, Christine
Gollob, Jared
机构：
[1] Christ Hosp, Cincinnati, OH USA
[2] Kymera Therapeut, Watertown, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3171
引用
收藏
页数：1
相关论文
共 50 条
  • [41] A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)
    Erba, Harry P.
    Oluwole, Olalekan O.
    Bixby, Dale
    Rampal, Raajit K.
    Fathi, Amir T.
    Paliwal, Prashni
    Jin, Jin
    Inoue, Ai
    Daver, Naval
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S311 - S312
  • [42] Rive-CLL: Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
    McKay, John
    Al-Juhaishi, Taha
    Lai Guanhua
    Kmieciak, Maciej
    Sabo, Roy
    Sindel, Ariel
    Yazbeck, Victor
    BLOOD, 2019, 134
  • [43] A PHASE 1 STUDY OF CEMIPLIMAB IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY (R/R) SOLID AND CENTRAL NERVOUS SYSTEM (CNS) TUMORS
    Kline, Cassie
    Schoenfeld, Jonathan D.
    Catalano, Paul J.
    Li, Jingjin
    Paccaly, Anne J.
    Sims, Tasha N.
    Bredlau, Amy-Lee
    Prados, Michael
    Haas-Kogan, Daphne
    Mueller, Sabine
    NEURO-ONCOLOGY, 2019, 21 : 220 - 220
  • [44] Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updated Long Term Results of Phase II Study
    Xu, Wei
    Song, Yongping
    Wang, Tingyu
    Yang, Shenmiao
    Liu, Lihong
    Hu, Yu
    Zhang, Wei
    Zhou, Jianfeng
    Gao, Sujun
    Ding, Kaiyang
    Zhang, Huilai
    Zhu, Zunmin
    Wang, Shunqing
    Xu, Bing
    Hu, Jianda
    Liu, Ting
    Ji, Chunyan
    Xia, Zhongjun
    Li, Yan
    Wang, Xin
    Bin Zhang
    Zhao, Renbin
    Li, Jianyong
    BLOOD, 2021, 138
  • [45] Phase 1 Study of Oxaliplatin and Irinotecan in Pediatric Patients With Refractory Solid Tumors
    McGregor, Lisa M.
    Spunt, Sheri L.
    Furman, Wayne L.
    Stewart, Clinton F.
    Schaiquevich, Paula
    Krailo, Mark D.
    Speights, RoseAnne
    Ivy, Percy
    Adamson, Peter C.
    Blaney, Susan M.
    CANCER, 2009, 115 (08) : 1765 - 1775
  • [46] Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia
    Flinn, Ian W.
    Gribben, John G.
    Dyer, Martin J. S.
    Wierda, William
    Maris, Michael B.
    Furman, Richard R.
    Hillmen, Peter
    Rogers, Kerry A.
    Iyer, Swaminathan Padmanabhan
    Quillet-Mary, Anne
    Ysebaert, Loic
    Walter, Harriet S.
    Verdugo, Maria
    Klein, Christian
    Huang, Huang
    Jiang, Yanwen
    Lozanski, Gerard
    Pignataro, Daniela Soriano
    Humphrey, Kathryn
    Mobasher, Mehrdad
    Kipps, Thomas J.
    BLOOD, 2019, 133 (26) : 2765 - 2775
  • [47] A Phase 1/2 study evaluating the safety and efficacy of IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
    Long, Meixiao
    Woyach, Jennifer
    Pinilla-Ibarz, Javier
    Stephens, Deborah M.
    Cacovean, Alex
    Fiaz, Rana
    Goldberg, Zelanna
    Jagasia, Madan
    Finckenstein, Friedrich Graf
    Fardis, Maria
    Byrd, C.
    CANCER RESEARCH, 2021, 81 (13)
  • [48] A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
    Barr, Paul M.
    Ma, Shuo
    Zent, Clive S.
    Baran, Andrea M.
    Bui, Andrew
    Meacham, Philip J.
    Morrison, Ashley
    Holkovic, Kelsey
    Liesveld, Jane L.
    Mulford, Deborah A.
    Sportelli, Peter
    Miskin, Hari P.
    Weiss, Michael S.
    Friedberg, Jonathan W.
    Hill, Brian T.
    BLOOD, 2020, 136
  • [49] Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan
    Katsuyoshi Koh
    Chitose Ogawa
    Yasuhiro Okamoto
    Kazuko Kudo
    Jiro Inagaki
    Tsuyoshi Morimoto
    Hideya Mizukami
    Evelyne Ecstein-Fraisse
    Atsushi Kikuta
    International Journal of Hematology, 2016, 104 : 245 - 255
  • [50] Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan
    Koh, Katsuyoshi
    Ogawa, Chitose
    Okamoto, Yasuhiro
    Kudo, Kazuko
    Inagaki, Jiro
    Morimoto, Tsuyoshi
    Mizukami, Hideya
    Ecstein-Fraisse, Evelyne
    Kikuta, Atsushi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 104 (02) : 245 - 255
12345